Zhang Fuhong, Chen Xiaowan, Xi Kehu, Qiu Zhiqiang, Wang Youhu, Gui Yan, Hou Yun, Chen Kangbing, Zhang Xiaobing
Department of Otolaryngology Head and Neck Surgery, First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China,
Onco Targets Ther. 2018 Nov 5;11:7827-7840. doi: 10.2147/OTT.S184303. eCollection 2018.
HOXD antisense growth-associated long noncoding RNA (HOXD-AS1) was reported to be upregulated in various cancers, such as gastric cancer, hepatocellular carcinoma, colorectal cancer, and glioma. Here, we conducted a meta-analysis and The Cancer Genome Atlas data review to investigate the clinicopathologic and prognostic value of HOXD-AS1 in patients with malignant tumors. Systematic literatures were searched from PubMed, Medline, Cochrane Library, Web of Science, EMBASE database, Ovid, Chinese CNKI, and the Chinese WanFang database. The role of HOXD-AS1 in cancers was evaluated by pooled ORs and HRs with 95% CIs. The Cancer Genome Atlas dataset was used to explore the prognostic value of HOXD-AS1 in various cancers.
Fifteen studies with 1,678 patients were included in this meta-analysis. The results indicated that HOXD-AS1 was associated with tumor size, differentiation, lymph node metastasis, and TNM stage. Moreover, the high HOXD-AS1 expression indicated a poor overall survival (OS) rate and can be an independent predictive factor for OS. The TCGA dataset, which included 9,502 cancer patients, showed that the expression of HOXD-AS1 was related to poor OS and disease-free survival. We also analyzed the prognostic role in different kinds of cancers such as digestive cancers, female reproductive system cancers, respiratory system cancers, and urinary system cancers.
This study demonstrated that HOXD-AS1 was closely correlated with tumor size, lymph node metastasis, distant metastasis, and TNM stage, and an increased HOXD-AS1 expression could be a reliable prognostic biomarker in human cancers. However, more studies are needed to confirm this conclusion.
据报道，HOXD反义生长相关长链非编码RNA（HOXD-AS1）在多种癌症中上调，如胃癌、肝细胞癌、结直肠癌和神经胶质瘤。在此，我们进行了一项荟萃分析和癌症基因组图谱数据回顾，以研究HOXD-AS1在恶性肿瘤患者中的临床病理和预后价值。从PubMed、Medline、Cochrane图书馆、Web of Science、EMBASE数据库、Ovid、中国知网和中国万方数据库中检索系统文献。通过合并的比值比（OR）和风险比（HR）及95%置信区间（CI）评估HOXD-AS1在癌症中的作用。利用癌症基因组图谱数据集探索HOXD-AS1在各种癌症中的预后价值。
本荟萃分析纳入了15项研究，共1678例患者。结果表明，HOXD-AS1与肿瘤大小、分化、淋巴结转移和TNM分期相关。此外，HOXD-AS1高表达表明总生存率（OS）较差，并且可以作为OS的独立预测因素。包含9502例癌症患者的TCGA数据集显示，HOXD-AS1的表达与较差的OS和无病生存率相关。我们还分析了其在消化系统癌症、女性生殖系统癌症、呼吸系统癌症和泌尿系统癌症等不同类型癌症中的预后作用。
本研究表明，HOXD-AS1与肿瘤大小、淋巴结转移、远处转移和TNM分期密切相关，HOXD-AS1表达增加可能是人类癌症中一个可靠的预后生物标志物。然而，需要更多研究来证实这一结论。
